Nebilet (Nebivolol)

Nebivolol blocks β1‑adrenergic receptors in the heart, reducing heart rate and contractile force. At the same time it enhances nitric‑oxide release from the endothelium, causing vasodilation and lowering peripheral vascular resistance, which together lower blood pressure.

The appropriate dose of Nebilet is determined by the prescribing clinician based on the individual’s medical condition, age, renal function, and response to therapy. Patients should follow the dose and titration schedule provided by their healthcare professional.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Nebilet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nebilet (nebivolol) is a β1‑selective blocker with added nitric‑oxide‑mediated vasodilation, which may offer better tolerability regarding metabolic effects compared with non‑selective beta‑blockers. It is often considered when patients need heart‑rate control without the adverse metabolic profile seen with some older agents.

Nebilet tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Nebilet is taken orally as a tablet, usually with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, severe dizziness, difficulty breathing, or swelling of the face or throat.

Nebilet is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, in those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with uncompensated heart failure or cardiogenic shock. Clinicians should also exercise caution in patients with asthma, COPD, or significant liver impairment.